Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement
March 31 2020 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
it has appointed Steven T. Gill as Vice President, Thought Leader
Engagement. Mr. Gill rejoins Alimera from Novartis US where he was
Associate Director, Thought Leader Liaison. In this newly created
position at Alimera, Mr. Gill will have the responsibility to
advocate for Alimera with physician and professional societies,
further driving Alimera’s mission to be invaluable to patients,
physicians and partners concerned with retinal health. He will
focus on leading a team that will improve customer access by
building long term relationships with physicians and key opinion
leaders.
“We are extremely pleased to welcome Steve back to Alimera in
this new role intended to elevate our advocacy among key opinion
leaders and drive increased peer-to-peer engagement between
customers currently using ILUVIEN® and those exploring its use in
their practices,” said Rick Eiswirth, Alimera’s President and Chief
Executive Officer. “Steve joins us at a time when the need to
reduce the recurrence of retinal disease and provide better vision
with fewer visits to the physician’s office for treatment
potentially becomes more evident.”
Mr. Gill added “I am honored and excited to rejoin Alimera and
work with their dedicated team that is committed to the retina
community, and the patients they serve. I look forward to working
across Alimera's entire commercial organization to increase
customer awareness and understanding of ILUVIEN and to improve the
lives of patients diagnosed with diabetic macular edema.”
Mr. Gill has over 20 years of experience in the medical field,
with 16 of those years specifically, in retina. Prior to his recent
role at Novartis where he was a member of the Beovu launch team
building advocacy and peer-to-peer marketing strategies, Mr. Gill
served at Alimera as Senior Director, Thought Leader Liaison.
His broad experience includes roles as a Medical Science Liaison at
Ophthotech, and multiple roles at Eyetech pharmaceuticals where he
served as a Regional Sales Director prior to taking a role as a
Medical Science Liaison. Mr. Gill earned his B.A. in
Organizational Communications at California State University,
Sacramento.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in
the commercialization and development of prescription ophthalmic
pharmaceuticals for the management of retinal diseases. Alimera is
presently focused on diseases affecting the back of the eye, or
retina, because these diseases are not well treated with current
therapies and will affect millions of people in our aging
populations. For more information, please visit
www.alimerasciences.com.
About
ILUVIEN®
The Company’s primary product is ILUVIEN (fluocinolone acetonide
intravitreal implant) 0.19 mg sustained release intravitreal
implant, injected into the back of the eye. With its CONTINUOUS
MICRODOSING™ technology, ILUVIEN is designed to release
sub-microgram levels of fluocinolone acetonide, a corticosteroid,
for 36 months, to reduce the recurrence of disease, enabling
patients to maintain vision longer with fewer injections. ILUVIEN
is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E. to
treat diabetic macular edema (DME) in patients who have been
previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure. In 17
European countries, ILUVIEN is indicated for the treatment of
vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. In March 2019,
ILUVIEN received approval in the 17 countries under the Mutual
Recognition Procedure for prevention of relapse in recurrent
non-infectious uveitis affecting the posterior segment of the eye.
The 17 European countries include the U.K., Germany, France, Italy,
Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway,
Finland, Sweden, Poland, Czech Republic, the Netherlands, and
Luxembourg. The non-infectious posterior uveitis indication for
ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is
not approved for treatment of uveitis in the United States.
Forward Looking Statements
This press release may include “forward-looking statements,”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change these
expectations, and could cause actual results to differ materially
from those projected in these forward-looking statements.
Meaningful factors that could cause actual results to differ
include but are not limited to, physicians and patients may not
perceive the benefit of better vision with fewer visits to the
physician’s office for treatment, Mr. Gill may not be able to
increase customer awareness and understanding of ILUVIEN to the
extent anticipated, as well as the other factors discussed in the
“Risk Factors” and “Management’s Discussion and Analysis of
Financial Condition and Results of Operations” sections of
Alimera’s Annual Report on Form 10-K for the year ended
December 31, 2019 which is on file with the Securities and
Exchange Commission (SEC) and available on the SEC’s website at
http://www.sec.gov.
For press inquiries:Jules Abrahamfor Alimera
Sciences 917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024